Euglycemic ketoacidosis [76], which characterizes patients with T1D being treated with SGLT2is, poses a serious challenge for the clinician, as patients may present with glucose levels in the normal range, leading to a potential delay in the appropriate management of the DKA [74]; this risk persists when SGLT2-is are combined with GLP1-agonists [77,78,79,80]. This evidence concerns the gene GCG and type 1 diabetes mellitus.